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Sarah Haebe1 and Oliver Weigert1,2*Abstract
Harnessing the immune system to attack tumor cells by targeting tumor-associated or –preferably– tumor-specific
antigens has emerged as a promising but challenging treatment option for malignant lymphomas. Follicular
lymphoma is among the most common lymphomas worldwide and remains incurable for most patients.
Considered to be an immunogenic disease it represents an interesting disease entity for various
immunotherapeutic approaches.
In an article published in the May issue of Clinical Cancer Research, Nielsen and colleagues provided important
proof-of-principle data on the immunogenicity of follicular lymphoma that might represent a first step towards
personalized adoptive immunotherapies in this disease. The authors combined targeted next-generation
sequencing and in silico analyses to explore the concept of somatic neoepitope prediction. Neoantigen-specific
CD8+ T-cells could be identified in a small subset of patients selected for in vitro immunogenicity experiments,
however at remarkably low frequencies and in only a few patients at single time-points. Of note, the immunogenic
neoepitopes were derived from mutant CREBBP and MEF2B, two genes that have previously been shown to be
functionally and prognostically relevant in this disease.
In this commentary we discuss the promises but also the challenges of how to translate these findings into clinical practice.
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Harnessing the immune system to attack tumor cells has
emerged as a promising but challenging treatment
option for malignant lymphomas. A recent breakthrough
in cancer immunotherapy has been declared when
immune checkpoint blockade with antibodies directed
against programmed-death 1 (PD-1) have resulted in
objective response rates in up to 87% in patients with
relapsed and refractory Hodgkin lymphomas [1, 2]. Non-
Hodgkin lymphomas also respond to PD-1 blockade,
including the two most common subtypes, follicular and
diffuse large B-cell lymphomas, but the rate and quality
of treatment responses are much less impressive [3].
In principle, PD-1 blockade acts by interfering with
tumor-induced immune tolerance and unleashes a pre-
exiting anti-tumor response directed against a variety of* Correspondence: oliver.weigert@med.uni-muenchen.de
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epitopes that may not be tumor-specific and contribute
to autoimmune-like or inflammatory side effects [4].
Also, low numbers and functionality of immune effector
cells will limit the clinical efficacy of this approach.
Immune effector cells can be expanded ex vivo, an
approach referred to as adoptive cellular immunother-
apy. E.g., expanded autologous antitumor lymphocytes
resulted in tumor regression in up to 70% in patients
with melanoma [5]. Tumor-reactive T-cells have also
been identified in lymphoid malignancies [6, 7].
Nielsen et al. recently provided interesting data that
might represent a first step towards personalized adoptive
immunotherapies in patients with follicular lymphoma [8].Main text
In their manuscript “Toward Personalized Lymphoma
Immunotherapy: Identification of Common Driver
Mutations Recognized by Patient CD8+ T Cells”, Nielsen
et al. explored the concept of somatic neoepitope predic-
tion and assessed the functionality of autologous CD8+le is distributed under the terms of the Creative Commons Attribution 4.0
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tive somatic neoepitopes, customized targeted next-
generation sequencing was performed on 53 lymphoma
samples, capturing ten genes that are known to be recur-
rently altered in malignant lymphomas and considered
oncogenic drivers of the disease. Non-synonymous
mutations were identified in 81% of patients. Using in
silico algorithms, 37 of 43 patients harbored mutations
that were predicted to form specific epitopes with
sufficient binding affinity to the patients’ HLA class I
haplotypes. From the 13 patients who were selected for
in vitro immunogenicity experiments, three had detect-
able autologous mutation-specific CD8+ T-cells as
confirmed by in vitro T-cell recognition of transfected
autologous B-cells. The immunogenic neoepitopes were
derived from mutant CREBBP and MEF2B, two genes
that have previously been shown to be functionally and
prognostically relevant in this disease [9–11].Conclusion and perspective
Can follicular lymphoma –again– serve as a prototype
example for the successful introduction of innovative
immunotherapeutic approaches? Two decades ago, the
advent of monoclonal anti-CD20 antibodies marked the
end of a treatment period now known as the pre-
rituximab era. Generally considered an immunogenic
disease with occasional waxing-and-waning lymphaden-
opathy and sporadic spontaneous regressions, follicular
lymphomas can harbor more than 100 coding mutations
that could potentially serve as tumor-specific neoepi-
topes [12]. Any mutation, including functionally
irrelevant, so-called bystander mutations can produce
immunogenic neoantigens, as long as they are
transcribed and translated, and their gene products
properly processed and presented onto a fitting HLA
haplotype. An earlier study performed in melanoma
patients receiving CTLA-4 antibodies could indeed dem-
onstrate that the mutational load (and distinct neoanti-
gen patterns) correlated with the immunogenicity and
clinical benefit to immune checkpoint inhibition [13]. In
that regard, it may come as a surprise that Nielsen et al.
did not identify neoantigen-specific T-cells in the major-
ity of patients with follicular lymphoma and that
substantial efforts were required to detect some at
remarkably low frequencies and in only a few patients at
single time-points. On the other hand, it will be interest-
ing to see if detectable neoantigen-reactive T-cells could
serve as biomarkers to predict response to immune
checkpoint inhibition in this disease.
It is likely that the authors would have identified more
neoantigen-reactive T-cells in a higher fraction of
patients with follicular lymphoma had they performed
exome-wide analyses. However, the rationale behindtargeting a limited number of gene mutations presumed
to be acquired early in the molecular ontogeny of the
disease and to drive the malignant phenotype is to
minimize the risk of subclone selection and immune
escape variants [14, 15]. Still, identifying these target
genes remains a major challenge, given our incomplete
understanding of the molecular biology of a disease as
molecularly diverse and genetically unstable as follicular
lymphoma. But even if directed against known driver
gene mutations, immune evasion from effective CD8+
T-cell mediated anti-tumor responses might occur via
loss of HLA, as recently described in a case of KRAS-
mutant metastatic colorectal cancer [16].
Eventually, it remains to be proven if these autologous
neoantigen-reactive CD8+ T-cells, even after ex vivo
expansion, will elicit an effective immune response in
patients and ultimately eradicate the disease. In contrast,
engineered T-cells have already shown clinical activity.
Promising response rates have been reported with
autologous T-cells transduced with a chimeric antigen
receptor directed against the pan B-cell marker CD19
for patients with refractory or relapsed B-cell malignan-
cies [17]. To reduce on- and off-target toxicity, T-cells
have been successfully engineered to target tumor-
specific epitopes. E.g., engineered T-cells directed against
the cancer-testis antigens NY-ESO-1 and LAGE-1
resulted in objective responses in 80% of patients with
advanced multiple myeloma, without causing clinically
apparent cytokine release syndromes [18].
In summary, from a scientific point of view, Nielsen
et al. provide important proof-of-principle data on the im-
munogenicity of follicular lymphoma. From a translational
research point of view, it remains unclear how to most
effectively bring these findings into clinical practice.
Rather exploratory, e.g. to determine the most promising
neoantigen-haplotype patterns for immunotherapeutic ap-
proaches? Or diagnostically, e.g. as biomarkers to predict
response to immune checkpoint inhibitors? Or therapeut-
ically, e.g. as actual immune effector cells to personalize
adoptive immunotherapy? From a clinical point of view,
numerous questions remain to be addressed. E.g., how to
select the subset of patients with follicular lymphoma who
qualify for and are expected to gain most benefit from
what type of personalized immunotherapy? How to
incorporate personalized immunotherapeutic concepts
into current treatment algorithms? And finally, how will
they compare to the numerous other promising treatment
options in terms of efficacy, toxicity, and –last but not
least– cost? But for those of us who share Bon Scott’s
Rock ‘n’ Roll point of view, all these challenges do not
come as a surprise: It’s a long way to the top…Acknowledgements
Not applicable.
Haebe and Weigert Journal for ImmunoTherapy of Cancer  (2017) 5:6 Page 3 of 3Funding
OW is supported by the Max-Eder Program of the Deutsche Krebshilfe e.V.
(110659) and the Deutsche Forschungsgemeinschaft (DFG-SFB/CRC-1243, TP-A11).
Availability of data and materials
Not applicable.
Authors’ contributions




The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Received: 23 November 2016 Accepted: 28 December 2016
References
1. Ansell SM, et al. PD-1 blockade with nivolumab in relapsed or refractory
Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–9.
2. Armand P, et al. Programmed death-1 blockade with pembrolizumab in
patients with classical hodgkin lymphoma after brentuximab vedotin failure.
J Clin Oncol. 2016;34(33):3733–39.
3. Lesokhin AM, et al. Nivolumab in patients with relapsed or refractory
hematologic malignancy: preliminary results of a phase Ib study. J Clin
Oncol. 2016;34(23):2698–704.
4. Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint
pathway. N Engl J Med. 2016;375(18):1767–78.
5. Dudley ME, et al. Cancer regression and autoimmunity in patients after clonal
repopulation with antitumor lymphocytes. Science. 2002;298(5594):850–4.
6. Rajasagi M, et al. Systematic identification of personal tumor-specific
neoantigens in chronic lymphocytic leukemia. Blood. 2014;124(3):453–62.
7. Riva G, et al. BCR-ABL-specific cytotoxic T cells in the bone marrow of
patients with Ph(+) acute lymphoblastic leukemia during second-generation
tyrosine-kinase inhibitor therapy. Blood Cancer J. 2011;1(7):e30.
8. Nielsen JS, et al. Toward personalized lymphoma immunotherapy:
identification of common driver mutations recognized by patient CD8+ T
cells. Clin Cancer Res. 2016;22(9):2226–36.
9. Pasqualucci L, et al. Inactivating mutations of acetyltransferase genes in
B-cell lymphoma. Nature. 2011;471(7337):189–95.
10. Ying CY, et al. MEF2B mutations lead to deregulated expression of the oncogene
BCL6 in diffuse large B cell lymphoma. Nat Immunol. 2013;14(10):1084–92.
11. Pastore A, et al. Integration of gene mutations in risk prognostication for
patients receiving first-line immunochemotherapy for follicular lymphoma: a
retrospective analysis of a prospective clinical trial and validation in a
population-based registry. Lancet Oncol. 2015;16(9):1111–22.
12. Morin RD, et al. Frequent mutation of histone-modifying genes in non-
Hodgkin lymphoma. Nature. 2011;476(7360):298–303.
13. Snyder A, et al. Genetic basis for clinical response to CTLA-4 blockade in
melanoma. N Engl J Med. 2014;371(23):2189–99.
14. Kasajima A, et al. Down-regulation of the antigen processing machinery is
linked to a loss of inflammatory response in colorectal cancer. Hum Pathol.
2010;41(12):1758–69.
15. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating
immunity’s roles in cancer suppression and promotion. Science.
2011;331(6024):1565–70.
16. Tran E, et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
N Engl J Med. 2016;375(23):2255–62.
17. Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions
in leukemia. N Engl J Med. 2014;371(16):1507–17.
18. Rapoport AP, et al. NY-ESO-1-specific TCR-engineered T cells mediate
sustained antigen-specific antitumor effects in myeloma. Nat Med.
2015;21(8):914–21.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
